{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T13:24:47Z","timestamp":1790861087200,"version":"4.1.0"},"reference-count":105,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Opinion in Virology"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1016\/j.coviro.2012.07.004","type":"journal-article","created":{"date-parts":[[2012,7,28]],"date-time":"2012-07-28T12:02:26Z","timestamp":1343476946000},"page":"572-579","source":"Crossref","is-referenced-by-count":34,"title":["Human viral diseases: what is next for antiviral drug discovery?"],"prefix":"10.1016","volume":"2","author":[{"given":"Erik","family":"De Clercq","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coviro.2012.07.004_bib0005","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.ijantimicag.2008.10.010","article-title":"Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV","volume":"33","author":"De Clercq","year":"2009","journal-title":"International Journal of Antimicrobial Agents"},{"key":"10.1016\/j.coviro.2012.07.004_bib0010","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/rmv.624","article-title":"The history of antiretrovirals: key discoveries over the past 25 years","volume":"19","author":"De Clercq","year":"2009","journal-title":"Reviews in Medical Virology"},{"key":"10.1016\/j.coviro.2012.07.004_bib0015","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/med.21267","article-title":"Tenofovir: quo vadis anno 2012 (where is it going in the year 2012)?","volume":"32","author":"De Clercq","year":"2012","journal-title":"Medicinal Research Reviews"},{"key":"10.1016\/j.coviro.2012.07.004_bib0020","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.bcp.2012.03.024","article-title":"Where rilpivirine meets with tenofovir, the start of a new anti-HIV drug combination era","volume":"84","author":"De Clercq","year":"2012","journal-title":"Biochemical Pharmacology"},{"key":"10.1016\/j.coviro.2012.07.004_bib0025","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(11)60983-5","article-title":"Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial","volume":"378","author":"Cohen","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.coviro.2012.07.004_bib0030","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0140-6736(11)60936-7","article-title":"Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial","volume":"378","author":"Molina","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.coviro.2012.07.004_bib0035","series-title":"19th Conference on Retroviruses and Opportunistic Infections","article-title":"Week 48 results of an ongoing global phase 3 study comparing elvitegravir\/cobicistat\/emtricitabine\/tenofovir (Quad) with atazanavir\/ritonavir plus emtricitabine\/tenofovir in treatment-na\u00efve HIV-1+ subjects showing efficacy, safety, and pharmacokinetics","author":"DeJesus","year":"2012"},{"key":"10.1016\/j.coviro.2012.07.004_bib0040_1","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1056\/NEJMoa1011205","article-title":"Preexposure chemoprophylaxis for HIV prevention in men who have sex with men","volume":"363","author":"Grant","year":"2010","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.coviro.2012.07.004_bib0045_1","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1126\/science.1193748","article-title":"Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women","volume":"329","author":"Abdool Karim","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.coviro.2012.07.004_bib0050_1","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa1105243","article-title":"Prevention of HIV-1 infection with early antiretroviral therapy","volume":"365","author":"Cohen","year":"2011","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.coviro.2012.07.004_bib0055","doi-asserted-by":"crossref","first-page":"312","DOI":"10.7326\/0003-4819-156-4-201202210-00383","article-title":"Antiretroviral medication and HIV prevention: new steps forward and new questions","volume":"156","author":"Mayer","year":"2012","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/j.coviro.2012.07.004_bib0060","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1097\/COH.0b013e32834fc1df","article-title":"Interventions to improve the performance of HIV health systems for treatment-as-prevention in sub-Saharan Africa: the experimental evidence","volume":"7","author":"B\u00e4rnighausen","year":"2012","journal-title":"Current Opinion in HIV and AIDS"},{"key":"10.1016\/j.coviro.2012.07.004_bib0065","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/COH.0b013e3283504ab7","article-title":"Treatment as prevention: translating efficacy trial results to population effectiveness","volume":"7","author":"Garnett","year":"2012","journal-title":"Current Opinion in HIV and AIDS"},{"key":"10.1016\/j.coviro.2012.07.004_bib0070","doi-asserted-by":"crossref","unstructured":"De Clercq E: The race for interferon-free HCV therapies: a snapshot by the spring of 2012. Reviews in Medical Virology 2012, in press.","DOI":"10.1002\/rmv.1727"},{"key":"10.1016\/j.coviro.2012.07.004_bib0075","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial","volume":"358","author":"Manns","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.coviro.2012.07.004_bib0080","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection","volume":"347","author":"Fried","year":"2002","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.coviro.2012.07.004_bib0085","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1056\/NEJMoa0808010","article-title":"Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection","volume":"361","author":"McHutchison","year":"2009","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.coviro.2012.07.004_bib0090","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1056\/NEJMoa0908014","article-title":"Telaprevir for previously treated chronic HCV infection","volume":"362","author":"McHutchison","year":"2010","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.coviro.2012.07.004_bib0095","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1009482","article-title":"Boceprevir for previously treated chronic HCV genotype 1 infection","volume":"364","author":"Bacon","year":"2011","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.coviro.2012.07.004_bib0100","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nature08960","article-title":"Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect","volume":"465","author":"Gao","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2012.07.004_bib0105","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1021\/jm201384j","article-title":"Nucleoside, nucleotide, and non-nucleoside inhibitors of hepatitis C virus NS5B RNA-dependent RNA-polymerase","volume":"55","author":"Sofia","year":"2012","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.coviro.2012.07.004_bib0110","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jcv.2011.08.003","article-title":"Current management and recommendations for access to antiviral therapy of herpes labialis","volume":"53","author":"Cunningham","year":"2012","journal-title":"Journal of Clinical Virology"},{"key":"10.1016\/j.coviro.2012.07.004_bib0115","doi-asserted-by":"crossref","first-page":"e34635","DOI":"10.1371\/journal.pone.0034635","article-title":"Infant safety during and after maternal valacyclovir therapy in conjunction with antiretroviral HIV-1 prophylaxis in a randomized clinical trial","volume":"7","author":"Drake","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.coviro.2012.07.004_bib0120","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1093\/infdis\/jir766","article-title":"Valacyclovir suppressive therapy reduces plasma and breast milk HIV-1 RNA levels during pregnancy and postpartum: a randomized trial","volume":"205","author":"Drake","year":"2012","journal-title":"Journal of Infectious Diseases"},{"key":"10.1016\/j.coviro.2012.07.004_bib0125","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1093\/infdis\/jir649","article-title":"High-dose valacyclovir HSV-2 suppression results in greater reduction in plasma HIV-1 levels compared with standard dose acyclovir among HIV-1\/HSV-2 coinfected persons: a randomized, crossover trial","volume":"204","author":"Mugwanya","year":"2011","journal-title":"Journal of Infectious Diseases"},{"key":"10.1016\/j.coviro.2012.07.004_bib0130","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1002\/jmv.22194","article-title":"Treatment with valacyclovir, famciclovir, or antiretrovirals reduces human herpesvirus-8 replication in HIV-1 seropositive men","volume":"83","author":"Cattamanchi","year":"2011","journal-title":"Journal of Medical Virology"},{"key":"10.1016\/j.coviro.2012.07.004_bib0135","series-title":"Abstracts of the Twenty-Fifth International Conference on Antiviral Research (ICAR)","article-title":"Excellent efficacy and pharmacokinetics have been demonstrated in pre-clinical and phase I\/II studies by AIC316, a novel drug against herpes simplex virus (HSV) type 1 and 2","author":"Birkmann","year":"2012"},{"key":"10.1016\/j.coviro.2012.07.004_bib0140","series-title":"Abstracts of the Twenty-Fifth International Conference on Antiviral Research (ICAR)","article-title":"Sensitivity of clinical isolates to helicase primase inhibitors and no detection of resistant mutations above background frequency","author":"Field","year":"2012"},{"key":"10.1016\/j.coviro.2012.07.004_bib0145_1","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/nm0402-392","article-title":"New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease","volume":"8","author":"Kleymann","year":"2002","journal-title":"Nature Medicine"},{"key":"10.1016\/j.coviro.2012.07.004_bib0150","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1128\/AAC.46.6.1766-1772.2002","article-title":"Potent in vivo antiviral activity of the herpes simplex virus primase-helicase inhibitor BAY 57-1293","volume":"46","author":"Betz","year":"2002","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.coviro.2012.07.004_bib0155","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.antiviral.2006.11.006","article-title":"The helicase primase inhibitor, BAY 57-1293 shows potent therapeutic antiviral activity superior to famciclovir in BALB\/c mice infected with herpes simplex virus type 1","volume":"75","author":"Biswas","year":"2007","journal-title":"Antiviral Research"},{"key":"10.1016\/j.coviro.2012.07.004_bib0160","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1093\/jac\/dkm182","article-title":"Detection of HSV-1 variants highly resistant to the helicase-primase inhibitor BAY 57-1293 at high frequency in 2 of 10 recent clinical isolates of HSV-1","volume":"60","author":"Biswas","year":"2007","journal-title":"Journal of Antimicrobial Chemotherapy"},{"key":"10.1016\/j.coviro.2012.07.004_bib0165","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1093\/jac\/dkq135","article-title":"Mismatch primer-based PCR reveals that helicase-primase inhibitor resistance mutations pre-exist in herpes simplex virus type 1 clinical isolates and are not induced during incubation with the inhibitor","volume":"65","author":"Sukla","year":"2010","journal-title":"Journal of Antimicrobial Chemotherapy"},{"key":"10.1016\/j.coviro.2012.07.004_bib0170","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.antiviral.2010.04.008","article-title":"Effects of therapy using a helicase-primase inhibitor (HPI) in mice infected with deliberate mixtures of wild-type HSV-1 and an HPI-resistant UL5 mutant","volume":"87","author":"Sukla","year":"2010","journal-title":"Antiviral Research"},{"key":"10.1016\/j.coviro.2012.07.004_bib0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/095632020801900101","article-title":"Herpes simplex virus helicase-primase inhibitors: recent findings from the study of drug resistance mutations","volume":"19","author":"Biswas","year":"2008","journal-title":"Antiviral Chemistry and Chemotherapy"},{"key":"10.1016\/j.coviro.2012.07.004_bib0180","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1093\/infdis\/jis019","article-title":"ASP2151 for the treatment of genital herpes: a randomized, double-blind, placebo- and valacyclovir-controlled, dose-finding study","volume":"205","author":"Tyring","year":"2012","journal-title":"Journal of Infectious Diseases"},{"key":"10.1016\/j.coviro.2012.07.004_bib0185","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1517\/14728214.2011.591786","article-title":"Emerging drugs for varicella-zoster virus infections","volume":"16","author":"Andrei","year":"2011","journal-title":"Expert Opinion on Emerging Drugs"},{"key":"10.1016\/j.coviro.2012.07.004_bib0190","doi-asserted-by":"crossref","first-page":"4479","DOI":"10.1021\/jm990346o","article-title":"Potent and selective inhibition of varicella-zoster virus (VZV) by nucleoside analogues with an unusual bicyclic base","volume":"42","author":"McGuigan","year":"1999","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.coviro.2012.07.004_bib0195","doi-asserted-by":"crossref","first-page":"4993","DOI":"10.1021\/jm000210m","article-title":"Highly potent and selective inhibition of varicella-zoster virus by bicyclic furopyrimidine nucleosides bearing an aryl side chain","volume":"43","author":"McGuigan","year":"2000","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.coviro.2012.07.004_bib0200_1","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1128\/AAC.49.3.1081-1086.2005","article-title":"Susceptibilities of several clinical varicella-zoster virus (VZV) isolates and drug-resistant VZV strains to bicyclic furano pyrimidine nucleosides","volume":"49","author":"Andrei","year":"2005","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.coviro.2012.07.004_bib0205","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/med.10035","article-title":"Highly potent and selective inhibition of varicella-zoster virus replication by bicyclic furo[2,3-d]pyrimidine nucleoside analogues","volume":"23","author":"De Clercq","year":"2003","journal-title":"Medicinal Research Reviews"},{"key":"10.1016\/j.coviro.2012.07.004_bib0210","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1093\/jac\/dkm376","article-title":"Preclinical development of bicyclic nucleoside analogues as potent and selective inhibitors of varicella zoster virus","volume":"60","author":"McGuigan","year":"2007","journal-title":"Journal of Antimicrobial Chemotherapy"},{"key":"10.1016\/j.coviro.2012.07.004_bib0215","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1128\/AAC.01446-10","article-title":"Pharmacokinetics and safety of FV-100, a novel oral anti-herpes zoster nucleoside analogue, administered in single and multiple doses to healthy young adult and elderly adult volunteers","volume":"55","author":"Pentikis","year":"2011","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.coviro.2012.07.004_bib0220","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ajo.2010.10.018","article-title":"Cytomegalovirus retinitis and the acquired immunodeficiency syndrome--bench to bedside: LXVII Edward Jackson Memorial Lecture","volume":"151","author":"Jabs","year":"2011","journal-title":"American Journal of Ophthalmology"},{"key":"10.1016\/j.coviro.2012.07.004_bib0225","doi-asserted-by":"crossref","first-page":"e24334","DOI":"10.1371\/journal.pone.0024334","article-title":"An artemisinin-derived dimer has highly potent anti-cytomegalovirus (CMV) and anti-cancer activities","volume":"6","author":"He","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.coviro.2012.07.004_bib0230","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1111\/j.1600-6143.2011.03530.x","article-title":"First report of successful treatment of multidrug-resistant cytomegalovirus disease with the novel anti-CMV compound AIC246","volume":"11","author":"Kaul","year":"2011","journal-title":"American Journal of Transplantation"},{"key":"10.1016\/j.coviro.2012.07.004_bib0235","first-page":"181","article-title":"Tecovirimat, a p37 envelope protein inhibitor for the treatment of smallpox infection","volume":"13","author":"Duraffour","year":"2010","journal-title":"IDrugs"},{"key":"10.1016\/j.coviro.2012.07.004_bib0240","doi-asserted-by":"crossref","first-page":"4999","DOI":"10.1128\/AAC.00678-09","article-title":"ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation","volume":"53","author":"Berhanu","year":"2009","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.coviro.2012.07.004_bib0245","doi-asserted-by":"crossref","first-page":"653","DOI":"10.2217\/fvl.11.27","article-title":"Development of the small-molecule antiviral ST-246 as a smallpox therapeutic","volume":"6","author":"Grosenbach","year":"2011","journal-title":"Future Virology"},{"key":"10.1016\/j.coviro.2012.07.004_bib0250_1","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.3390\/v2112409","article-title":"Development of ST-246\u00ae for treatment of poxvirus infections","volume":"2","author":"Jordan","year":"2010","journal-title":"Viruses"},{"key":"10.1016\/j.coviro.2012.07.004_bib0255","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.3390\/v2122681","article-title":"Treatment of vaccinia and cowpox virus infections in mice with CMX001 and ST-246","volume":"2","author":"Quenelle","year":"2010","journal-title":"Viruses"},{"key":"10.1016\/j.coviro.2012.07.004_bib0260","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1128\/AAC.00762-07","article-title":"Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses","volume":"51","author":"Quenelle","year":"2007","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.coviro.2012.07.004_bib0265","doi-asserted-by":"crossref","first-page":"e23237","DOI":"10.1371\/journal.pone.0023237","article-title":"Comparison of the safety and pharmacokinetics of ST-246\u00ae after i.v. infusion or oral administration in mice, rabbits and monkeys","volume":"6","author":"Chen","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.coviro.2012.07.004_bib0270","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.vaccine.2010.10.039","article-title":"Impact of ST-246\u00ae on ACAM2000\u2122 smallpox vaccine reactogenicity, immunogenicity, and protective efficacy in immunodeficient mice","volume":"29","author":"Berhanu","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2012.07.004_bib0275","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1073\/pnas.0912134107","article-title":"Efficacy of ST-246 versus lethal poxvirus challenge in immunodeficient mice","volume":"107","author":"Grosenbach","year":"2010","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.coviro.2012.07.004_bib0280","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1128\/JVI.02012-09","article-title":"A mouse model of lethal infection for evaluating prophylactics and therapeutics against monkeypox virus","volume":"84","author":"Stabenow","year":"2010","journal-title":"Journal of Virology"},{"key":"10.1016\/j.coviro.2012.07.004_bib0285","doi-asserted-by":"crossref","first-page":"9176","DOI":"10.1128\/JVI.02173-10","article-title":"Effective antiviral treatment of systemic orthopoxvirus disease: ST-246 treatment of prairie dogs infected with monkeypox virus","volume":"85","author":"Smith","year":"2011","journal-title":"Journal of Virology"},{"key":"10.1016\/j.coviro.2012.07.004_bib0290","series-title":"Abstracts of the Twenty-Fifth International Conference on Antiviral Research (ICAR)","article-title":"Therapeutic efficacy of ST-246 in cynomolgous macaques challenged with monkeypox virus via aerosol","author":"Russo","year":"2012"},{"key":"10.1016\/j.coviro.2012.07.004_bib0295","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/clpt.2010.178","article-title":"Update on new antivirals under development for the treatment of double-stranded DNA virus infections","volume":"88","author":"Dropulic","year":"2010","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1016\/j.coviro.2012.07.004_bib0300","series-title":"Abstracts of the Twenty-Fifth International Conference on Antiviral Research (ICAR)","article-title":"FMCA phosphoramidate prodrug: in vitro antiviral activity against lamivudine, adefovir and entecavir resistant HBV mutants and preliminary in vivo anti-HBV activity against the entecavir-lamivudine resistant triple mutant in chimeric mice","author":"Chu","year":"2012"},{"key":"10.1016\/j.coviro.2012.07.004_bib0305","doi-asserted-by":"crossref","first-page":"6328","DOI":"10.1016\/j.bmcl.2011.08.113","article-title":"Antiviral activity of novel 2\u2019-fluoro-6\u2019-methylene-carbocyclic adenosine against wild-type and drug-resistant hepatitis B virus mutants","volume":"21","author":"Wang","year":"2011","journal-title":"Bioorganic and Medicinal Chemistry Letters"},{"key":"10.1016\/j.coviro.2012.07.004_bib0310","doi-asserted-by":"crossref","first-page":"e34165","DOI":"10.1371\/journal.pone.0034165","article-title":"MicroRNA-141 represses HBV replication by targeting PPARA","volume":"7","author":"Hu","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.coviro.2012.07.004_bib0315","doi-asserted-by":"crossref","first-page":"e36363","DOI":"10.1371\/journal.pone.0036363","article-title":"A novel inhibitor of human La protein with anti-HBV activity discovered by structure-based virtual screening and in vitro evaluation","volume":"7","author":"Tang","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.coviro.2012.07.004_bib0320","doi-asserted-by":"crossref","first-page":"3118","DOI":"10.1016\/j.bmc.2009.03.003","article-title":"Synthesis and anti-hepatitis B virus activities of Matijing-Su derivatives","volume":"17","author":"Xu","year":"2009","journal-title":"Bioorganic and Medicinal Chemistry"},{"key":"10.1016\/j.coviro.2012.07.004_bib0325","doi-asserted-by":"crossref","first-page":"5352","DOI":"10.1016\/j.bmc.2011.08.001","article-title":"Synthesis and biological evaluation of Matijing-Su derivatives as potent anti-HBV agents","volume":"19","author":"Qiu","year":"2011","journal-title":"Bioorganic and Medicinal Chemistry"},{"key":"10.1016\/j.coviro.2012.07.004_bib0330","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1016\/j.bmc.2012.03.023","article-title":"Synthesis, structure-activity relationships and biological evaluation of caudatin derivatives as novel anti-hepatitis B virus agents","volume":"20","author":"Wang","year":"2012","journal-title":"Bioorganic and Medicinal Chemistry"},{"key":"10.1016\/j.coviro.2012.07.004_bib0335","doi-asserted-by":"crossref","first-page":"3473","DOI":"10.1016\/j.bmcl.2012.03.081","article-title":"Synthesis, biological evaluation and structure-activity relationships of glycyrrhetinic acid derivatives as novel anti-hepatitis B virus agents","volume":"22","author":"Wang","year":"2012","journal-title":"Bioorganic and Medicinal Chemistry Letters"},{"key":"10.1016\/j.coviro.2012.07.004_bib0340","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1002\/med.20125","article-title":"Selective inhibitors of picornavirus replication","volume":"28","author":"De Palma","year":"2008","journal-title":"Medicinal Research Reviews"},{"key":"10.1016\/j.coviro.2012.07.004_bib0345","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1093\/infdis\/jir745","article-title":"Antiviral activity of coxsackievirus B3 3C protease inhibitor in experimental murine myocarditis","volume":"205","author":"Yun","year":"2012","journal-title":"Journal of Infectious Diseases"},{"key":"10.1016\/j.coviro.2012.07.004_bib0350","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s00705-011-1222-6","article-title":"In vitro and in vivo evaluation of ribavirin and pleconaril antiviral activity against enterovirus 71 infection","volume":"157","author":"Zhang","year":"2012","journal-title":"Archives of Virology"},{"key":"10.1016\/j.coviro.2012.07.004_bib0355","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jmb.2012.01.049","article-title":"A template RNA entry channel in the fingers domain of the poliovirus polymerase","volume":"417","author":"Kortus","year":"2012","journal-title":"Journal of Molecular Biology"},{"key":"10.1016\/j.coviro.2012.07.004_bib0360","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1743-422X-9-26","article-title":"Enterovirus 71 viral capsid protein linear epitopes: identification and characterization","volume":"9","author":"Gao","year":"2012","journal-title":"Virology Journal"},{"key":"10.1016\/j.coviro.2012.07.004_bib0365","doi-asserted-by":"crossref","first-page":"6406","DOI":"10.1074\/jbc.M111.301622","article-title":"Molecular determinants of enterovirus 71 viral entry: cleft around GLN-172 on VP1 protein interacts with variable region on scavenge receptor B 2","volume":"287","author":"Chen","year":"2012","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.coviro.2012.07.004_bib0370","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1056\/NEJMp0910479","article-title":"The Emergency Use Authorization of peramivir for treatment of 2009 H1N1 influenza","volume":"361","author":"Birnkrant","year":"2009","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.coviro.2012.07.004_bib0375","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1093\/cid\/cir001","article-title":"Clinical experience in adults and children treated with intravenous peramivir for 2009 influenza A (H1N1) under an Emergency IND program in the United States","volume":"52","author":"Fernandez","year":"2011","journal-title":"Clinical Infectious Diseases"},{"key":"10.1016\/j.coviro.2012.07.004_bib0380","doi-asserted-by":"crossref","first-page":"4568","DOI":"10.1128\/AAC.00474-10","article-title":"Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection","volume":"54","author":"Kohno","year":"2010","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.coviro.2012.07.004_bib0385","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3851\/IMP1688","article-title":"Laninamivir and its prodrug, CS-8958: long-acting neuraminidase inhibitors for the treatment of influenza","volume":"21","author":"Yamashita","year":"2010","journal-title":"Antiviral Chemistry and Chemotherapy"},{"key":"10.1016\/j.coviro.2012.07.004_bib0390","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1177\/0091270009356297","article-title":"Clinical pharmacokinetics of laninamivir, a novel long-acting neuraminidase inhibitor, after single and multiple inhaled doses of its prodrug, CS-8958, in healthy male volunteers","volume":"50","author":"Ishizuka","year":"2010","journal-title":"Journal of Clinical Pharmacology"},{"key":"10.1016\/j.coviro.2012.07.004_bib0395","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1128\/AAC.01755-09","article-title":"Long-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) versus oseltamivir as treatment for children with influenza virus infection","volume":"54","author":"Sugaya","year":"2010","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.coviro.2012.07.004_bib0400","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1086\/656802","article-title":"Long-acting neuraminidase inhibitor laninamivir octanoate versus oseltamivir for treatment of influenza: a double-blind, randomized, noninferiority clinical trial","volume":"51","author":"Watanabe","year":"2010","journal-title":"Clinical Infectious Diseases"},{"key":"10.1016\/j.coviro.2012.07.004_bib0405","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1038\/nrd2175","article-title":"Antiviral agents active against influenza A viruses","volume":"5","author":"De Clercq","year":"2006","journal-title":"Nature Reviews Drug Discovery"},{"key":"10.1016\/j.coviro.2012.07.004_bib0410","doi-asserted-by":"crossref","first-page":"17959","DOI":"10.1021\/ja207892q","article-title":"A practical synthesis of zanamivir phosphonate congeners with potent anti-influenza activity","volume":"133","author":"Shie","year":"2011","journal-title":"Journal of the American Chemical Society"},{"key":"10.1016\/j.coviro.2012.07.004_bib0415","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1021\/mp200291x","article-title":"Enhancing the intestinal membrane permeability of zanamivir: a carrier mediated prodrug approach","volume":"8","author":"Gupta","year":"2011","journal-title":"Molecular Pharmaceutics"},{"key":"10.1016\/j.coviro.2012.07.004_bib0420","doi-asserted-by":"crossref","first-page":"e29778","DOI":"10.1371\/journal.pone.0029778","article-title":"Triple combination antiviral drug (TCAD) composed of amantadine, oseltamivir, and ribavirin impedes the selection of drug-resistant influenza A virus","volume":"6","author":"Hoopes","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.coviro.2012.07.004_bib0425","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.antiviral.2012.03.001","article-title":"Combinations of favipiravir and peramivir for the treatment of pandemic influenza A\/California\/04\/2009 (H1N1) virus infections in mice","volume":"94","author":"Tarbet","year":"2012","journal-title":"Antiviral Research"},{"key":"10.1016\/j.coviro.2012.07.004_bib0430","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1021\/jm2013503","article-title":"Design, synthesis, and in vitro biological evaluation of 1H-1,2,3-triazole-4-carboxamide derivatives as new anti-influenza A agents targeting virus nucleoprotein","volume":"55","author":"Cheng","year":"2012","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.coviro.2012.07.004_bib0435","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1111\/j.1747-0285.2012.01344.x","article-title":"Synthesis and preliminary biologic evaluation of 5-substituted-2-(4-substituted phenyl)-1,3-benzoxazoles as a novel class of influenza virus A inhibitors","volume":"79","author":"Li","year":"2012","journal-title":"Chemical Biology & Drug Design"},{"key":"10.1016\/j.coviro.2012.07.004_bib0440","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.bbagen.2011.11.003","article-title":"Structure-based discovery of anti-influenza virus A compounds among medicines","volume":"1820","author":"Fukuoka","year":"2012","journal-title":"Biochimica et Biophysica Acta"},{"key":"10.1016\/j.coviro.2012.07.004_bib0445","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1016\/j.bmcl.2012.01.056","article-title":"Synthesis and anti-influenza activity of aminoalkyl rupestonates","volume":"22","author":"Zhao","year":"2012","journal-title":"Bioorganic and Medicinal Chemistry Letters"},{"key":"10.1016\/j.coviro.2012.07.004_bib0450","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s12272-012-0406-2","article-title":"Design, synthesis, and anti-influenza viral activities of 1,3-diarylprop-2-en-1-ones: a novel class of neuraminidase inhibitors","volume":"35","author":"Kinger","year":"2012","journal-title":"Archives of Pharmacal Research"},{"key":"10.1016\/j.coviro.2012.07.004_bib0455","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.ejmech.2012.04.022","article-title":"Structure-activity relationships of saponin derivatives: a series of entry inhibitors for highly pathogenic H5N1 influenza virus","volume":"53","author":"Ding","year":"2012","journal-title":"European Journal of Medical Chemistry"},{"key":"10.1016\/j.coviro.2012.07.004_bib0460","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.phymed.2011.07.004","article-title":"In vitro anti-influenza virus activity of a cardiotonic glycoside from Adenium obesum (Forssk.)","volume":"19","author":"Kiyohara","year":"2012","journal-title":"Phytomedicine"},{"key":"10.1016\/j.coviro.2012.07.004_bib0465","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1186\/1743-422X-8-538","article-title":"Anti-influenza virus effect of aqueous extracts from dandelion","volume":"8","author":"He","year":"2011","journal-title":"Virology Journal"},{"key":"10.1016\/j.coviro.2012.07.004_bib0470","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.bmcl.2011.10.119","article-title":"Synthesis and antiviral activity of substituted quercetins","volume":"22","author":"Thapa","year":"2012","journal-title":"Bioorganic and Medicinal Chemistry Letters"},{"key":"10.1016\/j.coviro.2012.07.004_bib0475","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.antiviral.2012.03.006","article-title":"EPs\u00ae 7630 (Umckaloabo\u00ae), an extract from Pelargonium sidoides roots, exerts anti-influenza virus activity in vitro and in vivo","volume":"94","author":"Theisen","year":"2012","journal-title":"Antiviral Research"},{"key":"10.1016\/j.coviro.2012.07.004_bib0480","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.antiviral.2012.02.013","article-title":"Antiviral effects of Psidium guajava Linn. (guava) tea on the growth of clinical isolated H1N1 viruses: its role in viral hemagglutination and neuraminidase inhibition","volume":"94","author":"Sriwilaijaroen","year":"2012","journal-title":"Antiviral Research"},{"key":"10.1016\/j.coviro.2012.07.004_bib0485","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.antiviral.2012.04.001","article-title":"In vitro anti-influenza virus and anti-inflammatory activities of theaflavin derivatives","volume":"94","author":"Zu","year":"2012","journal-title":"Antiviral Research"},{"key":"10.1016\/j.coviro.2012.07.004_bib0490","doi-asserted-by":"crossref","first-page":"66","DOI":"10.3382\/ps.2011-01645","article-title":"Anti-influenza virus activity of green tea by-products in vitro and efficacy against influenza virus infection in chickens","volume":"91","author":"Lee","year":"2012","journal-title":"Poultry Science"},{"key":"10.1016\/j.coviro.2012.07.004_bib0495","doi-asserted-by":"crossref","first-page":"3157","DOI":"10.1073\/pnas.0909587107","article-title":"A broad-spectrum antiviral targeting entry of enveloped viruses","volume":"107","author":"Wolf","year":"2010","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.coviro.2012.07.004_bib0500","doi-asserted-by":"crossref","first-page":"17339","DOI":"10.1073\/pnas.1010026107","article-title":"Rigid amphipathic fusion inhibitors, small molecule antiviral compounds against enveloped viruses","volume":"107","author":"St Vincent","year":"2010","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.coviro.2012.07.004_bib0505_1","series-title":"Abstracts of the Twenty-Fifth International Conference on Antiviral Research (ICAR)","article-title":"The RAFIs aUY11 and dUY11 inhibit infectivity of unrelated enveloped viruses by prevention fusion of viral and cellular membranes","author":"Colpitts","year":"2012"},{"key":"10.1016\/j.coviro.2012.07.004_bib0510","series-title":"Abstracts of the Twenty-Fifth International Conference on Antiviral Research (ICAR)","article-title":"The green tea polyphenol epigallocatechin gallate inhibits infectivity of unrelated enveloped viruses by preventing primary attachment of virions to cells","author":"Colpitts","year":"2012"},{"key":"10.1016\/j.coviro.2012.07.004_bib0515","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1128\/AAC.01315-09","article-title":"Antiviral activity of a small-molecule inhibitor of filovirus infection","volume":"54","author":"Warren","year":"2010","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.coviro.2012.07.004_bib0520","first-page":"87","article-title":"FGI-104: a broad-spectrum small molecule inhibitor of viral infection","volume":"1","author":"Kinch","year":"2009","journal-title":"American Journal of Translational Research"},{"key":"10.1016\/j.coviro.2012.07.004_bib0525","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.antiviral.2009.06.001","article-title":"Development of a broad-spectrum antiviral with activity against Ebola virus","volume":"83","author":"Aman","year":"2009","journal-title":"Antiviral Research"}],"container-title":["Current Opinion in Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625712001095?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625712001095?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,21]],"date-time":"2018-11-21T15:31:13Z","timestamp":1542814273000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879625712001095"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10]]},"references-count":105,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["S1879625712001095"],"URL":"https:\/\/doi.org\/10.1016\/j.coviro.2012.07.004","relation":{},"ISSN":["1879-6257"],"issn-type":[{"value":"1879-6257","type":"print"}],"subject":[],"published":{"date-parts":[[2012,10]]}}}